PepGen(US:PEPG) Prnewswireยท2025-06-12 09:45Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of PepGen Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its lead product candidate, PGN-EDO51, and its clinical study, CONNECT2 [1][2]. Allegations - The complaint claims that during the class period from March 7, 2024, to March 3, 2025, PepGen's statements regarding PGN-EDO51's effectiveness and safety were misleading [1]. - It is alleged that the CONNECT2 study was dangerous or deficient for FDA approval, leading to the likelihood of halting the study [1]. - The lawsuit asserts that the clinical, regulatory, and commercial prospects of PGN-EDO51 were overstated, resulting in materially false public statements by the defendants [1]. Next Steps for Shareholders - Shareholders who purchased shares of PEPG during the specified timeframe are encouraged to register for the class action by August 8, 2025, to potentially become lead plaintiffs [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [2]. About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].